Recent legal changes, introduced by EA PO, allows to include national patents in the EA pharmaceutical registry (active from March 2021); however, not every member country is yet willing to submit actual information on its patents. Therefore, national registries of pharmaceutical patents are still necessary.
Russian registry is still in its prototype stage and it is expected that legal framework shall be finished soon. Yury Zubov, head of RU PTO, recently stressed a necessity of parallel registry, deriving from experience, already available in EAPO. The head of the latter, Grigory Ivliev, confirmed the EA legal base is ready and theoretically every claimant may add a national patent to EA registry. But not all national PTOs are willing to provide restricted information on the patents, so the registry is doomed to be incomplete till then.
In 2026, the Eurasian industrial design system marks its fifth anniversary. Over the past five…
On World Intellectual Property Day 2026, the World Intellectual Property Organization (WIPO) released new data…
Eduard Shablin, Partner at Patentica, participated in the second IP Eurasia mobile seminar held in…
Patentica participated in the INTA 2026 Annual Meeting held from May 2 to May 6,…
In 2025, the Eurasian patent system demonstrated steady growth in applicant activity. The number of…
The lawyers of Patentica have once again confirmed that infringement of intellectual property should not…